# Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID).

> **NCT02573038** · PHASE2 · WITHDRAWN · sponsor: **Hospices Civils de Lyon**

## Conditions studied

- Choroidal Neovascularization in Angioid Streaks

## Interventions

- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT02573038
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-02
- **Primary completion:** 2018-05
- **Final completion:** 2018-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02573038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02573038, "Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID).". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02573038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*